Core Viewpoint - Hendi Pharmaceutical has issued a profit warning for 2025, predicting a more than 90% drop in core profits, highlighting its reliance on ibuprofen raw materials and the challenges it faces in the market [1][15]. Financial Performance - The company expects a significant decline in net profit for 2025, estimating a range of 31 million to 39 million yuan, a year-on-year decrease of 57.40% to 66.14% [1][15]. - The projected non-recurring net profit for 2025 is estimated to be between 5.5 million and 8.2 million yuan, reflecting a year-on-year reduction of 88.76% to 92.46% [1][15]. - Total revenue for 2024 is projected at approximately 445.86 million yuan, a decrease of 32.75% compared to 2023 [3]. Business Dependency - Hendi Pharmaceutical primarily engages in the research, production, and sales of chemical raw materials and formulations, with a significant reliance on raw material revenue, which constitutes nearly 80% of its income [2][17]. - The company is the largest supplier of ibuprofen in China and the second largest globally [2][17]. Market Conditions - The global ibuprofen market is experiencing an imbalance in supply and demand, leading to a continuous decline in prices, which has significantly impacted the company's gross margin [1][15]. - Since 2020, the supply of ibuprofen raw materials in China has exceeded daily demand, contributing to a saturated market and declining prices [5][21]. Strategic Changes - The company has terminated its plan to expand ibuprofen production by 5,000 tons and is shifting focus towards formulation and CDMO (Contract Development and Manufacturing Organization) services [1][15][25]. - The company aims to enhance its market competitiveness through technological upgrades and by increasing research and development investments in new products [27]. Shareholder Actions - Major shareholders have begun to reduce their stakes in the company, which may indicate a lack of confidence in the company's short-term recovery prospects [1][14][29]. - Three shareholders plan to collectively reduce their holdings by up to 2.33% of the company's total shares [29].

Group 1 - The core point of the article is that Hendi Pharmaceutical (301211) reported its shareholder count as of January 9, 2026, which stands at 21,066 households [1]

Core Viewpoint - Hendi Pharmaceutical (301211.SZ) is currently experiencing a decline in stock price, with a closing price of 13.20 yuan and a market capitalization of 5.512 billion yuan, indicating it is in a state of share price drop since its IPO [1] Group 1: IPO Details - Hendi Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on December 22, 2021, with an initial public offering (IPO) of 60 million shares at a price of 25.80 yuan per share [1] - The total funds raised from the IPO amounted to 1.548 billion yuan, with a net amount of 1.401 billion yuan, exceeding the originally planned fundraising by 210 million yuan [1] - The company initially aimed to raise 1.19 billion yuan for various projects, including the production of 5,000 tons of ibuprofen raw materials and 1,200 tons of other raw materials [1] Group 2: Financial Announcements - On May 24, 2023, Hendi Pharmaceutical announced a stock bonus plan, proposing to increase the share capital by 2 shares for every 10 shares held, along with a pre-tax dividend of 4 yuan [2] - On August 1, 2025, the company announced another stock bonus plan, proposing to increase the share capital by 4.5 shares for every 10 shares held [3]

Group 1 - Hangxiao Steel Structure announced that it does not have a "commercial aerospace" business, with its main operations focused on steel structure contracting and related services, and a recent project contributing less than 1% to its 2024 audited revenue [1] - Tianlong Group stated that it has not generated additional revenue from AI tools, which are currently used internally for advertising content creation, and that the overall business operations remain unaffected [1] - Wanxing Technology confirmed that there are no undisclosed significant matters affecting its operations, and its business environment remains stable [2] Group 2 - Yaxing Chemical announced the termination of a share issuance and cash purchase of assets due to market changes and disagreements on asset valuation [2] - Zhejiang Shuculture clarified that its subsidiaries do not engage in GEO business, which has been misreported by media [2] - Luxshare Precision terminated the acquisition of assets from Wintime Technology due to delivery restrictions, with a request for the return of 1.53 billion RMB [3] Group 3 - Jinyu Group reported that its subsidiaries' revenues from specific projects are minimal compared to its overall revenue, with a small contribution from recent contracts [4] - Tongyu Communication highlighted that its stock price has significantly outpaced its fundamentals, indicating potential risks of a price correction [4] - Dongfang Mingzhu noted that the listing process for its investment in Chaoguhuan has uncertainties but currently does not impact its performance [5] Group 4 - Luyin Investment warned of risks associated with its stock price surge, which has increased by 86.92% over the last ten trading days [5] - Puyuan Information stated that its AI software platform is in the early commercialization stage, with limited revenue impact expected [6] - Zhejiang Wenhu Intermediary reported that its GEO business has not yet generated revenue, reflecting uncertainties in market acceptance [6] Group 5 - Xinhua News confirmed that its GEO business lacks a mature profit model and has not generated income [7] - People's Daily stated that it does not engage in GEO business and has not been affected by market rumors [7] - China First Heavy Industries reported minimal involvement in controllable nuclear fusion projects, with no significant revenue generated [8] Group 6 - Xibu Mining announced an increase in copper resources at the Yulong Copper Mine, adding 131.42 million tons of copper metal resources [8] - Jiurui New Materials commenced trial production of a new photoinitiator project, expected to cater to mainstream markets [9] - Tongda Sea indicated that AI-related revenue is low and does not significantly impact overall business performance [10] Group 7 - Zhenai Meijia's stock price has deviated significantly from market indices, prompting caution for investors [11] - Guizhou Moutai approved a new marketing strategy to enhance its sales channels and adapt to consumer demands [12] - Shunhao Co. plans to increase its stake in a subsidiary, reflecting confidence in future business prospects [14] Group 8 - A number of companies, including TCL Technology and Dazhu CNC, forecast significant profit increases for 2025, driven by operational improvements and market demand [19][22] - Long Cable Technology expects a profit increase due to changes in its employee stock plan and market conditions [22] - Jiangsu Electric Power reported a profit increase attributed to higher sales and reduced financial costs [29]

Core Viewpoint - Hendi Pharmaceutical (301211) anticipates a significant decline in performance for 2025, with net profit expected to drop by 57.40% to 66.14% year-on-year, amounting to between 31 million to 39 million yuan [1][3]. Financial Performance Summary - The projected net profit for 2025 is between 31 million and 39 million yuan, a decrease of 57.40% to 66.14% compared to the previous year [1][2]. - The expected non-recurring net profit for 2025 is between 550,000 and 820,000 yuan, reflecting a decline of 88.76% to 92.46% year-on-year [1][2]. - In the first three quarters of 2025, the company reported revenue of 319 million yuan, down 4.52% year-on-year, with a net profit of 20.93 million yuan, a decrease of 71.96% [3]. Market Position and Product Overview - Hendi Pharmaceutical is one of the six major global producers of ibuprofen raw materials and ranks second in domestic production and sales [3]. - The company's main products include ibuprofen, dexibuprofen, and torasemide, with ibuprofen and dexibuprofen being the primary revenue sources [3]. - The revenue share from the raw material drug segment has been consistently high, accounting for 79.88% in 2024, down from 83.65% in 2023 [4]. Sales and Strategy Adjustments - In 2024, the sales volume of ibuprofen decreased by 37.51% to 2,222.35 tons, leading to a revenue drop of 32.75% to 446 million yuan and a net profit of 9.155 million yuan, down 48.02% year-on-year [5]. - The company has adjusted its sales strategy in response to intense international market competition and low pricing for ibuprofen raw materials, resulting in reduced production and sales volumes [6]. - Hendi Pharmaceutical has also terminated its planned expansion project for ibuprofen production, reallocating funds towards research and development and safety upgrades for existing projects [6].

Core Viewpoint - Hendi Pharmaceutical (301211) forecasts a significant decline in net profit for 2025, estimating a range of 31 million to 39 million yuan, representing a year-on-year decrease of 57.4% to 66.14% [2] Group 1: Financial Performance - The company anticipates a net profit of 31 million to 39 million yuan for 2025, indicating a substantial decline compared to previous years [2] - The projected decline in net profit is attributed to intensified market competition for its main product, ibuprofen raw materials, and certain specialty raw materials, leading to a decrease in gross margin [2] Group 2: Market Conditions - Increased competition in the market for ibuprofen and specialty raw materials is a key factor contributing to the expected decline in profitability [2] - A reduction in interest income from cash management due to falling interest rates is also impacting the company's financial outlook [2]

Group 1 - Shoukai Co. achieved a signed area of 125.72 million square meters and a signed amount of 17.845 billion yuan in 2025 [1] - Tongda Hai expects a net loss for the year 2025 [2] - Jiuri New Materials' subsidiary has entered the trial production phase for a project with an annual capacity of 350 tons of hydroxy ketone [3] Group 2 - Jixin Technology's shareholder plans to reduce their stake by up to 1% [4] - Fulai New Materials received approval from the CSRC for a stock issuance [5] - Yaqi International plans to sign a strategic cooperation framework agreement with Zhongnong Holdings [6] Group 3 - Sanwei Co.'s controlling shareholder plans to transfer up to 5.10% of shares [7] - Lekai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film production line [8] - China Power Construction's subsidiary signed two major contracts totaling approximately 15.589 billion yuan [9] Group 4 - Shunhao Co. plans to increase its investment in a subsidiary by 74.98 million yuan [10] - Jieneng Wind Power reported a cumulative power generation of 12.417 billion kWh in 2025, a year-on-year increase of 1.43% [11] - Zhongjian Technology's H-share issuance application has been accepted by the CSRC [12] Group 5 - Hendi Pharmaceutical expects a net profit decrease of 57.4% to 66.14% in 2025 [13] - Haopeng Technology anticipates a net profit increase of 113.69% to 141.09% in 2025 [14] - Lingang Co. expects a net loss of 1.45 billion to 1.67 billion yuan in 2025 [15] Group 6 - Chuan Investment Energy reported a cumulative power generation of 6.627 billion kWh in 2025, a year-on-year increase of 13.85% [16] - Tengyuan Cobalt expects a net profit increase of 50.02% to 69.87% in 2025 [17] - Huazhi Jie plans to repurchase shares worth 30 million to 50 million yuan [18] Group 7 - Opto has won a bid for a 120 million yuan project from GoerTek [19] - Shanghai Construction reported a new contract amount of 252.942 billion yuan in 2025, a year-on-year decrease of 34.98% [20] - Hangfa Control expects a net profit decrease of 52.02% to 58.02% in 2025 [22] Group 8 - Shimao Energy is planning a change in control and will continue to suspend trading [23] - Shenwan Hongyuan Securities received approval for a bond issuance of up to 60 billion yuan [24] - Jingjiawei signed a strategic cooperation letter of intent with Jing'an Technology [25] Group 9 - Pianzaihuang completed the first subject enrollment for a clinical trial of a new drug [26] - Placo's subsidiary received a new veterinary drug registration certificate [27] - Zhongli Co. plans to reduce its stake by up to 0.75% [28] Group 10 - Solar Energy received renewable energy subsidies of 3.318 billion yuan in 2025, a year-on-year increase of 142.9% [29] - Palm Co. has filed a lawsuit to recover 144 million yuan in project payments [30][31] - Yongjin Co. plans to invest 2.658 billion yuan in a new stainless steel project [32] Group 11 - BAIC Blue Valley plans to increase its stake by 14.5 million to 16.4 million yuan [33] - Lingyun Light's stock issuance application has been approved by the CSRC [34] - Hongbo New Materials expects a net loss in 2025 [35] Group 12 - Shanghai Pharmaceuticals received approval for the listing of a new antifungal drug [36] - Changjiang Electric reported a net profit of 34.167 billion yuan in 2025, a year-on-year increase of 5.14% [37] - Weilan Bio received a new veterinary drug registration certificate [38] Group 13 - Pingzhi Information's subsidiary is expected to win a procurement project worth approximately 37.5884 million yuan [39]

Core Viewpoint - Hendi Pharmaceutical (301211.SZ) expects a significant decline in net profit for 2025, projecting a range of 31 million to 39 million yuan, which represents a decrease of 66.14% to 57.40% compared to the previous year [1] Financial Performance - The net profit attributable to shareholders is forecasted to be between 31 million and 39 million yuan, indicating a substantial decline from the previous year [1] - The net profit after excluding non-recurring gains and losses is expected to be between 5.5 million and 8.2 million yuan, reflecting a decrease of 92.46% to 88.76% year-on-year [1] Market Conditions - The decline in profit is attributed to intensified market competition for the main product, ibuprofen raw materials, and certain specialty raw material products, leading to a decrease in gross margin [1] - Additionally, the reduction in interest income from cash management due to falling interest rates has also impacted profitability [1]

Core Viewpoint - Hendi Pharmaceutical expects a significant decline in net profit for 2025, projecting a range of 31 million to 39 million yuan, which represents a year-on-year decrease of 66.14% to 57.40% [1] Group 1 - The primary reason for the profit decline is intensified market competition for its main product, ibuprofen raw materials, and certain specialty raw material products, leading to a decrease in gross margin [1] - Additionally, the company's cash management interest income has decreased due to falling interest rates [1]

证券代码：301211 证券简称：亨迪药业 公告编号：2026-001 湖北亨迪药业股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与会计师事 务所在本次业绩预告方面不存在重大分歧。 三、业绩变动原因说明 1、由于主产品布洛芬原料药及部分特色原料药产品市场竞争加剧，毛利率下降。 重要提示： 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形 单位：万元 | 项 目 | 本报告期 | | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 | 比上年同期 | 3,100 | ～ | 3,900 | 9,154.74 | | 东的净利润 | 下降 | 66.14% | ～ | 57.40% | | | 扣除非经常性损益 | 比上年同期 | 550 | ～ | 820 | 7,2 ...